Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Electra Gruppen in connection with its listing on NASDAQ OMX
Mandate

Vinge advises Electra Gruppen in connection with its listing on NASDAQ OMX

May 28, 2009

Vinge is advising Electra Gruppen AB in connection with its change of exchange listing from First North to NASDAQ OMX Stockholm. The first day of trading is estimated to be 1 June 2009.

Trading in respect of Electra Gruppen’s shares on First North will cease in connection with the listing on NASDAQ OMX. No new shares will be issued in connection with the listing.

Electra Gruppen owns chain stores selling home electronics and telecommunications products. The company was founded in 1949 and has its head office and conducts most of its operations in Kalmar. Electra Gruppen has approximately 90 employees.

Vinge’s team consists of responsible partner Jesper Ottergren together with associates Christian Lindhé, Marcus Bergdahl, Ida Christensson and Anna Bjering.

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026